

Sergio Amadori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3523916/publications.pdf>

Version: 2024-02-01

216
papers

24,540
citations

22153

59
h-index

7348

152
g-index

218
all docs

218
docs citations

218
times ranked

19253
citing authors

#	ARTICLE	IF	CITATIONS
1	AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – AMYNERVA-GIMEMA AML1919 trial. <i>Future Oncology</i> , 2021, 17, 3787-3796.	2.4	0
2	Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. <i>Leukemia</i> , 2020, 34, 914-918.	7.2	46
3	Survival Improvement over Time of 960 s-AML Patients Included in 13 EORTC-GIMEMA-HOVON Trials. <i>Cancers</i> , 2020, 12, 3334.	3.7	6
4	Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukaemia: Long-term follow up of a phase III study. <i>American Journal of Hematology</i> , 2020, 95, 749-758.	4.1	12
5	GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. <i>Blood</i> , 2019, 134, 935-945.	1.4	148
6	Genomic profiling and predicting treatment response in acute myeloid leukemia. <i>Pharmacogenomics</i> , 2019, 20, 467-470.	1.3	9
7	Health-related quality of life, symptom burden, and comorbidity in long-term survivors of acute promyelocytic leukemia. <i>Leukemia</i> , 2019, 33, 1598-1607.	7.2	15
8	Impact of induction regimen and allogeneic hematopoietic cell transplantation on outcome in younger adults with acute myeloid leukemia with a monosomal karyotype. <i>Haematologica</i> , 2019, 104, 1168-1175.	3.5	12
9	Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. <i>Expert Review of Hematology</i> , 2018, 11, 307-313.	2.2	21
10	Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome. <i>Seminars in Hematology</i> , 2018, 55, 209-214.	3.4	39
11	Longitudinal detection of DNMT3A ^{R882H} transcripts in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, E120-E123.	4.1	7
12	Cytogenetic clonal heterogeneity is not an independent prognosis factor in 15–60-year-old AML patients: results on 1291 patients included in the EORTC/GIMEMA AML-10 and AML-12 trials. <i>Annals of Hematology</i> , 2018, 97, 1785-1795.	1.8	4
13	Immunosenescence and Immunotherapy in Elderly Acute Myeloid Leukemia Patients: Time for a Biology-Driven Approach. <i>Cancers</i> , 2018, 10, 211.	3.7	8
14	Low-dose clofarabine in combination with a standard remission induction in patients aged 18–60 years with previously untreated intermediate and bad-risk acute myeloid leukemia or high-risk myelodysplastic syndrome: combined phase I/II results of the EORTC/GIMEMA AML-14A trial. <i>Haematologica</i> , 2017, 102, e47-e51.	3.5	5
15	Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. <i>New England Journal of Medicine</i> , 2017, 377, 454-464.	27.0	1,628
16	Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. <i>Blood</i> , 2017, 129, 424-447.	1.4	4,375
17	Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 605-612.	1.6	299
18	MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2016, 8, 2016052.	1.3	18

#	ARTICLE	IF	CITATIONS
19	A cluster of <i>Geotrichum clavatum</i> (<i>Saprochaete clavata</i>) infection in haematological patients: a first Italian report and review of literature. <i>Mycoses</i> , 2016, 59, 594-601.	4.0	44
20	Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia. <i>Haematologica</i> , 2016, 101, 77-85.	3.5	53
21	The optimal dosing of gemtuzumab ozagamicin: where to go from here?. <i>Haematologica</i> , 2016, 101, 653-654.	3.5	4
22	Gemtuzumab Ozogamicin Versus Best Supportive Care in Older Patients With Newly Diagnosed Acute Myeloid Leukemia Unsuitable for Intensive Chemotherapy: Results of the Randomized Phase III EORTC-GIMEMA AML-19 Trial. <i>Journal of Clinical Oncology</i> , 2016, 34, 972-979.	1.6	296
23	Biological monitoring of Italian soldiers deployed in Iraq. Results of the SIGNUM project. <i>International Journal of Hygiene and Environmental Health</i> , 2016, 219, 24-32.	4.3	7
24	Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies. <i>Annals of Hematology</i> , 2015, 94, 23-34.	1.8	12
25	A Leukemia-Associated CD34/CD123/CD25/CD99+ Immunophenotype Identifies <i>FLT3</i> -Mutated Clones in Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2015, 21, 3977-3985.	7.0	66
26	Idarubicin and cytarabine in combination with gemtuzumab ozogamicin (IAGO) for untreated patients with high-risk MDS or AML evolved from MDS: a phase II study from the EORTC and GIMEMA Leukemia Groups (protocol 06013). <i>Annals of Hematology</i> , 2015, 94, 1981-1989.	1.8	12
27	Extensive toxic epidermal necrolysis following brentuximab vedotin administration. <i>Annals of Hematology</i> , 2015, 94, 355-356.	1.8	9
28	Minimal residual disease as biomarker for optimal biologic dosing of $ARA\hat{C}$ in patients with acute myeloid leukemia. <i>American Journal of Hematology</i> , 2015, 90, 125-131.	4.1	12
29	Clinicopathologic Characterization of Diffuse-Large-B-Cell Lymphoma with an Associated Serum Monoclonal IgM Component. <i>PLoS ONE</i> , 2014, 9, e93903.	2.5	37
30	Remembering Professor Roberto Stasi (August 24th 1961 - January 28th 2014). <i>Haematologica</i> , 2014, 99, 794-794.	3.5	0
31	CENTRAL NERVOUS SYSTEM INVOLVEMENT IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: DIAGNOSTIC TOOLS, PROPHYLAXIS AND THERAPY. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2014, 6, e2014075.	1.3	50
32	A new system for quality control in hematopoietic progenitor cell units before reinfusion in autologous transplant. <i>Transfusion</i> , 2014, 54, 522-531.	1.6	1
33	Advances in the treatment of elderly and frail patients with acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2014, 26, 663-669.	2.4	4
34	Randomized Phase III Trial of Retinoic Acid and Arsenic Trioxide Versus Retinoic Acid and Chemotherapy in Patients With Acute Promyelocytic Leukemia: Health-Related Quality-of-Life Outcomes. <i>Journal of Clinical Oncology</i> , 2014, 32, 3406-3412.	1.6	76
35	Rituximab single agent in age-related Epstein-Barr virus associated B cell disorder complicated by autoimmune anemia and pure red cell aplasia. <i>Annals of Hematology</i> , 2014, 93, 1611-1612.	1.8	0
36	Clinical and biological impact of TET2 mutations and expression in younger adult AML patients treated within the EORTC/GIMEMA AML-12 clinical trial. <i>Annals of Hematology</i> , 2014, 93, 1401-12.	1.8	25

#	ARTICLE	IF	CITATIONS
37	High sensitivity of flow cytometry improves detection of occult leptomeningeal disease in acute lymphoblastic leukemia and lymphoblastic lymphoma. <i>Annals of Hematology</i> , 2014, 93, 1509-1513.	1.8	30
38	NOTCH1 mutations identify a chronic lymphocytic leukemia patient subset with worse prognosis in the setting of a rituximab-based induction and consolidation treatment. <i>Annals of Hematology</i> , 2014, 93, 1765-1774.	1.8	34
39	High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 219-228.	1.6	145
40	Invasive fungal diseases during first induction chemotherapy affect complete remission achievement and long-term survival of patients with acute myeloid leukemia. <i>Leukemia Research</i> , 2014, 38, 469-474.	0.8	33
41	Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2013, 369, 111-121.	27.0	1,284
42	Infections increase the risk of central venous catheter-related thrombosis in adult acute myeloid leukemia. <i>Thrombosis Research</i> , 2013, 132, 511-514.	1.7	41
43	Clinical significance of c.7544â€7545 del<sc>CT </sc><i><sc>NOTCH</sc>1</i> mutation in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2013, 160, 415-418.	2.5	14
44	Identification of emerging <i><sc>FLT</sc>3 </i><sc>ITD</sc>â€positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin. <i>British Journal of Haematology</i> , 2013, 161, 533-540.	2.5	39
45	Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients. <i>Expert Review of Hematology</i> , 2013, 6, 767-784.	2.2	23
46	Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). <i>Journal of Clinical Oncology</i> , 2013, 31, 4424-4430.	1.6	78
47	Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients. <i>Cell Cycle</i> , 2013, 12, 1815-1816.	2.6	4
48	TREATMENT OF ACUTE MYELOID LEUKEMIA WITH 20-30% BONE MARROW BLASTS. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2013, 5, e2013032.	1.3	3
49	Thoracic Cord Compression Caused by Epidural Extramedullary Hematopoiesis During Erythroid-Stimulating Agent Therapy in Two Patients With Myelodysplastic Syndromes. <i>Journal of Clinical Oncology</i> , 2013, 31, e189-e191.	1.6	7
50	Phase II Study of Bortezomib as a Single Agent in Patients with Previously Untreated or Relapsed/Refractory Acute Myeloid Leukemia Ineligible for Intensive Therapy. <i>Leukemia Research and Treatment</i> , 2013, 2013, 1-6.	2.0	17
51	Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. <i>Haematologica</i> , 2013, 98, 239-246.	3.5	268
52	Minimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?. <i>Translational Pediatrics</i> , 2013, 2, 43-5.	1.2	1
53	Value of infliximab (Remicade(R)) in patients with low-risk myelodysplastic syndrome: final results of a randomized phase II trial (EORTC trial 06023) of the EORTC Leukemia Group. <i>Haematologica</i> , 2012, 97, 529-533.	3.5	22
54	CD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling study. <i>Haematologica</i> , 2012, 97, 279-287.	3.5	32

#	ARTICLE	IF	CITATIONS
55	EORTC Leukemia Group achievements. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 94-98.	2.2	0
56	Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 332-341.	1.4	246
57	Intensive consolidation therapy compared with standard consolidation and maintenance therapy for adults with acute myeloid leukaemia aged between 46 and 60 years: final results of the randomized phase III study (AML 8B) of the European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. <i>Annals of Hematology</i> , 2012, 91, 825-835.	1.8	19
58	Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML1107). <i>British Journal of Haematology</i> , 2012, 156, 205-212.	2.5	65
59	Diffuse-Large-B-Cell Lymphoma Patients with Secretory IgM Monoclonal Component Are A Very Poor Prognostic Subset. <i>Blood</i> , 2012, 120, 2659-2659.	1.4	2
60	A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. <i>Oncotarget</i> , 2012, 3, 1615-1628.	1.8	54
61	Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse. <i>Blood</i> , 2011, 117, 3294-3301.	1.4	353
62	AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance. <i>Blood</i> , 2011, 117, 4716-4725.	1.4	173
63	Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia. <i>Blood</i> , 2011, 118, 6030-6036.	1.4	103
64	Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. <i>Experimental Hematology</i> , 2011, 39, 653-665.e6.	0.4	37
65	A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. <i>Leukemia and Lymphoma</i> , 2011, 52, 2329-2335.	1.3	7
66	Immunotherapeutic Maintenance Strategy Prolongs Response Duration and Overall Survival Preventing Relapse in Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2011, 118, 3906-3906.	1.4	1
67	Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. <i>Haematologica</i> , 2010, 95, 1489-1495.	3.5	19
68	Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial. <i>Haematologica</i> , 2010, 95, 1754-1761.	3.5	73
69	Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. <i>Blood</i> , 2010, 115, 2755-2762.	1.4	242
70	Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group. <i>Blood</i> , 2010, 116, 3171-3179.	1.4	290
71	Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. <i>Blood</i> , 2010, 116, 2295-2303.	1.4	126
72	Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. <i>Blood</i> , 2010, 115, 453-474.	1.4	2,963

#	ARTICLE	IF	CITATIONS
73	Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: Association of DNA breaks with specific DNA motifs at <i>PML</i> and <i>RARA</i> loci. <i>Genes Chromosomes and Cancer</i> , 2010, 49, 726-732.	2.8	32
74	Procalcitonin is a reliable marker of severe systemic infection in neutropenic haematological patients with mucositis. <i>American Journal of Hematology</i> , 2010, 85, 380-383.	4.1	12
75	Pyrrolo[1,2- <i>b</i>][1,2,5]benzothiadiazepines (PBTDs) exert their anti-proliferative activity by interfering with Akt/mTOR signaling and bax/bcl-2 ratio modulation in cells from chronic myeloid leukemic patients. <i>Cancer Science</i> , 2010, 101, 991-1000.	3.9	6
76	Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML19). <i>British Journal of Haematology</i> , 2010, 149, 376-382.	2.5	52
77	The genotype nucleophosmin mutated and <i>FLT3</i> Δ ITD negative is characterized by high bax/bcl-2 ratio and favourable outcome in acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2010, 149, 383-387.	2.5	15
78	Molecular characterization of paediatric idiopathic hypereosinophilia. <i>British Journal of Haematology</i> , 2010, 151, 440-446.	2.5	29
79	Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2010, 51, 95-106.	1.3	16
80	Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes. <i>Clinical Cancer Research</i> , 2009, 15, 5002-5007.	7.0	103
81	Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10. <i>Journal of Clinical Oncology</i> , 2009, 27, 5397-5403.	1.6	180
82	Simultaneous occurrence of BCR/ABL1 and RUNX1/RUNX1T1 in a case of therapy-related acute myeloid leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2009, 195, 189-191.	1.0	4
83	Identification of a potential "hotspot" DNA region in the <i>RUNX1</i> gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 213-221.	2.8	22
84	High-dose epoetin alfa as induction treatment for severe anemia in multiple myeloma patients. <i>International Journal of Hematology</i> , 2009, 90, 270-272.	1.6	4
85	Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2009, 146, 341-341.	2.5	10
86	<i>IKZF1</i> (Ikaros) Deletions in <i>BCR-ABL1</i> Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse: A GIMEMA AL WP Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 5202-5207.	1.6	276
87	Epstein-Barr virus-positive lymphoma after alemtuzumab therapy for B-cell chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 857-858.	1.3	2
88	Monitoring of minimal residual disease in acute myeloid leukemia. <i>Current Opinion in Oncology</i> , 2009, 21, 582-588.	2.4	24
89	Effects of eradication of <i>Helicobacter pylori</i> infection in patients with immune thrombocytopenic purpura: a systematic review. <i>Blood</i> , 2009, 113, 1231-1240.	1.4	273
90	Treatment of Adolescents and Young Adults with Acute Lymphoblastic Leukemia (ALL): An Update of the GIMEMA Experience.. <i>Blood</i> , 2009, 114, 3097-3097.	1.4	3

#	ARTICLE	IF	CITATIONS
91	Evaluation of the prognostic relevance of sialin and ICAM1 expression in myelodysplastic syndromes. <i>European Journal of Haematology</i> , 2008, 80, 107-114.	2.2	7
92	Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. <i>Cancer</i> , 2008, 112, 119-128.	4.1	86
93	Heterogeneity in the therapeutic approach to relapsed elderly patients with acute myeloid leukaemia: a survey from the Gruppo Italiano Malattie Ematologiche dell' Adulto (GIMEMA) Acute Leukaemia Working Party. <i>Hematological Oncology</i> , 2008, 26, 104-107.	1.7	8
94	Hodgkin lymphoma in a mutated ZAP-70 negative B-cell Chronic Lymphocytic Leukemia patient. <i>Leukemia Research</i> , 2008, 32, 363-365.	0.8	2
95	Rituximab in the treatment of autoimmune haematological disorders. <i>British Journal of Haematology</i> , 2008, 143, 294-294.	2.5	4
96	Liposomal daunorubicin versus standard daunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trial in patients older than 60 years with acute myelogenous leukaemia. <i>British Journal of Haematology</i> , 2008, 143, 681-689.	2.5	54
97	Novel Thrombopoietic Agents. <i>Drugs</i> , 2008, 68, 901-912.	10.9	64
98	An Allele-Specific RT-PCR Assay to Detect Type A Mutation of the Nucleophosmin-1 Gene in Acute Myeloid Leukemia. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 212-216.	2.8	36
99	Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. <i>Cancer Treatment Reviews</i> , 2008, 34, 49-60.	7.7	52
100	Toward Optimization of Postremission Therapy for Residual Disease-Positive Patients With Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 4944-4951.	1.6	165
101	A one-mutation mathematical model can explain the age incidence of acute myeloid leukemia with mutated nucleophosmin (NPM1). <i>Haematologica</i> , 2008, 93, 1219-1226.	3.5	23
102	Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. <i>Blood</i> , 2008, 112, 1147-1150.	1.4	353
103	Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. <i>Blood</i> , 2008, 111, 865-873.	1.4	226
104	Molecular analysis of t(15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. <i>Blood</i> , 2008, 112, 3383-3390.	1.4	74
105	Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia. <i>Current Opinion in Hematology</i> , 2008, 15, 95-100.	2.5	3
106	Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management. <i>Thrombosis and Haemostasis</i> , 2008, 99, 4-13.	3.4	239
107	Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia. <i>Haematologica</i> , 2008, 93, 1017-1024.	3.5	22
108	High Dose (HD-AraC) Vs Standard Dose Cytosine Arabinoside (SDAraC) during Induction and Value of IL-2 during Maintenance in Acute Myelogenous Leukemia (AML): Impact of AraC Dose on Complete Remission Rate and Toxicity (Results on the first 1700 randomized patients of the AML-12 trial of EORTC) <i>TJ ETQq000 rgBT /Overlock 1</i>	1.4	5

#	ARTICLE	IF	CITATIONS
109	Biologic Aspects of Thrombopoietin and the Development of Novel Thrombopoietic Agents for Clinical Use. <i>Current Drug Discovery Technologies</i> , 2007, 4, 162-173.	1.2	17
110	Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. <i>Blood</i> , 2007, 110, 2924-2930.	1.4	267
111	Activity and safety profile of low-dose rituximab for the treatment of autoimmune cytopenias in adults. <i>Haematologica</i> , 2007, 92, 1695-1698.	3.5	136
112	Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow. <i>Haematologica</i> , 2007, 92, 605-611.	3.5	76
113	Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura?. <i>Current Opinion in Hematology</i> , 2007, 14, 642-646.	2.5	34
114	Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. <i>Blood</i> , 2007, 109, 4143-4150.	1.4	352
115	Autologous stem cell transplantation after complete remission and first consolidation in acute myeloid leukemia patients aged 61-70 years: results of the prospective EORTC GIMEMA AML 13 study. <i>Haematologica</i> , 2007, 92, 389-396.	3.5	48
116	PYRROLO[1,2-b][1,2,5]BENZOTHIADIAZEPINES (PBTDs) induce apoptosis in K562 cells. <i>BMC Cancer</i> , 2007, 7, 207.	2.6	6
117	Novel role of triazines in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia. <i>DNA Repair</i> , 2007, 6, 1179-1186.	2.8	18
118	Diagnostic refinement of chronic myeloproliferative disorders and thrombocytoses of unknown origin by multiple RT-PCR and capillary electrophoresis of BCR-ABL rearrangements and JAK2 (V617F) mutation. <i>Annals of Hematology</i> , 2007, 86, 355-361.	1.8	2
119	Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. <i>Blood</i> , 2006, 108, 853-861.	1.4	171
120	Monoclonal antibodies and immunoconjugates in acute myeloid leukemia. <i>Best Practice and Research in Clinical Haematology</i> , 2006, 19, 715-736.	1.7	4
121	Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 374-387.	4.3	103
122	Pyrrolo[1,2-b][1,2,5]benzothiadiazepines (PBTDs): A New Class of Agents with High Apoptotic Activity in Chronic Myelogenous Leukemia K562 Cells and in Cells from Patients at Onset and Who Were Imatinib-Resistant. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 5840-5844.	6.4	56
123	Long-Term Outcome of Otherwise Healthy Individuals with Incidentally Discovered Borderline Thrombocytopenia. <i>PLoS Medicine</i> , 2006, 3, e24.	8.4	82
124	Complete regression of cutaneous lesions of refractory Ph+ ALL after 4 weeks of treatment with BMS-354825. <i>Blood</i> , 2006, 107, 4571-4572.	1.4	7
125	Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. <i>Blood</i> , 2006, 108, 1999-2005.	1.4	181
126	A prospective study comparing quantitative Cytomegalovirus (CMV) polymerase chain reaction in plasma and pp65 antigenemia assay in monitoring patients after allogeneic stem cell transplantation. <i>BMC Infectious Diseases</i> , 2006, 6, 167.	2.9	30

#	ARTICLE	IF	CITATIONS
127	Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2006, 85, 136-138.	1.8	5
128	Opioids in pain management of blood-related malignancies. <i>Annals of Hematology</i> , 2006, 85, 489-501.	1.8	19
129	Authors' Response to Zimmer et al. <i>PLoS Medicine</i> , 2006, 3, e365.	8.4	0
130	Sequential Valproic Acid/All-trans Retinoic Acid Treatment Reprograms Differentiation in Refractory and High-Risk Acute Myeloid Leukemia. <i>Cancer Research</i> , 2006, 66, 8903-8911.	0.9	125
131	Role of immunochemotherapy in the treatment of chronic lymphocytic leukemia. <i>Expert Review of Anticancer Therapy</i> , 2006, 6, 1787-1800.	2.4	4
132	High Dose (HD-AraC) vs Standard Dose Cytosine Arabinoside (SD-AraC) during Induction in Acute Myelogenous Leukemia (AML): Impact on Stem Cell Mobilization after Consolidation and on		

#	ARTICLE	IF	CITATIONS
145	Dexamethasone Versus Methyl-Prednisolone in Induction Therapy for Adult Acute Lymphoblastic (ALL) and Non-Hodgkin Lymphoma (NHL) Patients ≥ 60 Yrs Old: Final Results of the Eortc All-4 Phase III Trial.. Blood, 2005, 106, 1834-1834.	1.4	0
146	Chromosomal Aberration of the 11q23 Locus in Acute Leukemia and Frequency of <i>MLL</i> Gene Translocation. American Journal of Clinical Pathology, 2004, 122, 298-306.	0.7	49
147	Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation. The Hematology Journal, 2004, 5, 24-31.	1.4	6
148	CD90/Thy-1 is preferentially expressed on blast cells of high risk acute myeloid leukaemias*. British Journal of Haematology, 2004, 125, 203-212.	2.5	26
149	The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. British Journal of Haematology, 2004, 125, 232-239.	2.5	289
150	Factors associated with outcomes of unrelated cord blood transplant: Guidelines for donor choice. Experimental Hematology, 2004, 32, 397-407.	0.4	384
151	Collection of peripheral progenitor cells: a comparison between Amicus and Cobe-Spectra blood cell separators. Transfusion and Apheresis Science, 2004, 30, 131-136.	1.0	21
152	Selective B-cell depletion with rituximab for the treatment of patients with acquired hemophilia. Blood, 2004, 103, 4424-4428.	1.4	200
153	Comparison of rHuEpo plus rHuG-CSF and supportive care: apples to oranges. Blood, 2004, 104, 2201-2202.	1.4	3
154	Addition of Rituximab to Fludarabine Improves Progression Free Survival in Untreated ZAP-70 Negative Chronic Lymphocytic Leukemia (CLL).. Blood, 2004, 104, 477-477.	1.4	1
155	ZAP-70 Protein Retains Its Prognostic Significance within Interphase Cytogenetic Groups in B-Cell Chronic Lymphocytic Leukemia (B-CLL).. Blood, 2004, 104, 2806-2806.	1.4	1
156	Chromosomal Aberration of the 11q23 Locus in Acute Leukemia and Frequency of <i>MLL</i> Gene Translocation Results in 378 Adult Patients. American Journal of Clinical Pathology, 2004, 122, 298-306.	0.7	31
157	Sequential administration of gemtuzumab ozogamicin and conventional chemotherapy as first line therapy in elderly patients with acute myeloid leukemia: a phase II study (AML-15) of the EORTC and GIMEMA leukemia groups. Haematologica, 2004, 89, 950-6.	3.5	62
158	Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia. Haematologica, 2004, 89, 1468-75.	3.5	18
159	Cancer-related fatigue. Cancer, 2003, 98, 1786-1801.	4.1	439
160	P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia. British Journal of Haematology, 2003, 121, 730-738.	2.5	32
161	Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23+ /mll + translocation in leukaemia. British Journal of Haematology, 2003, 121, 953-955.	2.5	11
162	Low cell concentration of cryopreserved autologous CD34+ peripheral blood progenitor cells does not impair hematopoietic recovery after transplantation. Transfusion and Apheresis Science, 2003, 29, 189-192.	1.0	0

#	ARTICLE	IF	CITATIONS
163	Multidimensional Flow Cytometry for Detection of Minimal Residual Disease in Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 2003, 44, 445-450.	1.3	11
164	Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). <i>Blood</i> , 2003, 101, 2125-2131.	1.4	309
165	Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. <i>Blood</i> , 2003, 102, 1232-1240.	1.4	330
166	Comparison between conventional banding analysis and FISH screening with an AML-specific set of probes in 260 patients. <i>The Hematology Journal</i> , 2003, 4, 263-270.	1.4	27
167	Clinical Relevance of Minimal Residual Disease Detection in Adult Acute Myeloid Leukemia. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 349-357.	1.8	21
168	The Role of Angiogenesis in Hematologic Malignancies. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2002, 11, 49-68.	1.8	12
169	Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 years. <i>European Journal of Haematology</i> , 2002, 69, 200-204.	2.2	16
170	Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. <i>Blood</i> , 2002, 99, 863-871.	1.4	325
171	Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. <i>Blood</i> , 2002, 99, 1578-1584.	1.4	43
172	Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. <i>Blood</i> , 2002, 100, 3141-3146.	1.4	90
173	Variable patterns of response to rituximab treatment in adults with chronic idiopathic thrombocytopenic purpura. <i>Blood</i> , 2002, 99, 3872-3873.	1.4	108
174	Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors. <i>Transfusion and Apheresis Science</i> , 2002, 26, 103-110.	1.0	7
175	Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2002, 116, 334-337.	2.5	19
176	Infliximab chimaeric anti-tumour necrosis factor alpha monoclonal antibody treatment for patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2002, 116, 334-7.	2.5	13
177	Subcutaneous Administration of Interleukin-2 Triggers Fcγ ₃ Receptor I Expression on Human Peripheral Blood Neutrophils in Solid and Hematologic Malignancies. <i>Journal of Immunotherapy</i> , 2001, 24, 374-383.	2.4	2
178	CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production. <i>Blood</i> , 2001, 97, 3621-3627.	1.4	28
179	Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. <i>Blood</i> , 2001, 98, 952-957.	1.4	531
180	Clinical significance of CD38 expression in chronic lymphocytic leukemia. <i>Blood</i> , 2001, 98, 2633-2639.	1.4	242

#	ARTICLE	IF	CITATIONS
181	New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia. <i>Leukemia Research</i> , 2001, 25, 349-351.	0.8	13
182	A Novel t(11;12)(q23;q24) in a Case of Minimally-Differentiated Acute Myeloid Leukemia (AML-M0). <i>Cancer Genetics and Cytogenetics</i> , 2000, 118, 76-79.	1.0	3
183	Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. <i>Blood</i> , 2000, 96, 3948-3952.	1.4	225
184	Pulsed Intravenous High-Dose Dexamethasone in Adults with Chronic Idiopathic Thrombocytopenic Purpura. <i>Blood Cells, Molecules, and Diseases</i> , 2000, 26, 582-586.	1.4	41
185	Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. <i>Blood</i> , 2000, 96, 3948-3952.	1.4	60
186	Recombinant human granulocyte-macrophage colony-stimulating factor plus erythropoietin for the treatment of cytopenias in patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 1999, 105, 141-148.	2.5	43
187	P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia. <i>Leukemia Research</i> , 1999, 23, 451-465.	0.8	33
188	Nerve growth factor: a survey of activity on immune and hematopoietic cells. <i>Hematological Oncology</i> , 1999, 17, 1-10.	1.7	38
189	AML-M0: A Review of Laboratory Features and Proposal of New Diagnostic Criteria. <i>Blood Cells, Molecules, and Diseases</i> , 1999, 25, 120-129.	1.4	14
190	Automated Haematology Analysers in Acute and Chronic Leukaemias. <i>Acta Haematologica</i> , 1998, 100, 61-62.	1.4	0
191	A Comparative Analysis of FISH, RT-PCR, and Cytogenetics for the Diagnosis of <i>bcr-abl</i> Positive Leukemias. <i>American Journal of Clinical Pathology</i> , 1998, 109, 24-31.	0.7	39
192	Biological Features of Acute Myeloid Leukemia in the Elderly. <i>Blood</i> , 1998, 92, 697-699.	1.4	14
193	Prognostic Value of Cytogenetics and Multidrug Resistance (MDR1) in Elderly Patients With Acute Myeloid Leukemia. <i>Blood</i> , 1998, 92, 695-697.	1.4	9
194	Role of Human Leukocyte Interferon- γ in the Treatment of Patients With Polycythemia Vera. <i>American Journal of the Medical Sciences</i> , 1998, 315, 237-241.	1.1	7
195	P-Glycoprotein Expression in De Novo Acute Myeloid Leukemia. <i>Leukemia and Lymphoma</i> , 1997, 27, 257-274.	1.3	29
196	Minimally Differentiated Acute Myeloid Leukemia (AML-M0): Comparison of 25 Cases With Other French-American-British Subtypes. <i>Blood</i> , 1997, 89, 621-629.	1.4	75
197	A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype. <i>Leukemia Research</i> , 1997, 21, 575-580.	0.8	14
198	High-dose chemotherapy in adult acute myeloid leukemia: Rationale and results. <i>Leukemia Research</i> , 1996, 20, 535-549.	0.8	14

#	ARTICLE	IF	CITATIONS
199	Intensive treatment of patients age 60 years and older with De novo acute myeloid leukemia: Analysis of prognostic factors. , 1996, 77, 2476-2488.		38
200	Cytogenetic analysis is non-informative for assessing the remission rate in chronic myeloid leukemia (CML) patients on interferon- β (IFN- β) therapy. Cancer Genetics and Cytogenetics, 1995, 84, 15-18.	1.0	20
201	Long-Term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. American Journal of Medicine, 1995, 98, 436-442.	1.5	318
202	Anaplastic large cell lymphoma (CD30+/Ki-1+): results of a prospective clinico-pathological study of 69 cases. British Journal of Haematology, 1994, 86, 513-523.	2.5	100
203	Minimally differentiated acute myeloid leukaemia (AML-MO): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases. British Journal of Haematology, 1994, 88, 784-793.	2.5	46
204	Bisantrene in Relapsed and Refractory Acute Myelogenous Leukemia. Leukemia and Lymphoma, 1993, 9, 217-220.	1.3	3
205	Sequential Combination Chemotherapy of High-Grade Non-Hodgkin's Lymphoma with 5-Fluorouracil, Methotrexate, Cytosine-Arabinoside, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (F-MACHOP). Cancer Investigation, 1987, 5, 159-169.	1.3	29
206	Autologous bone marrow transplantation in acute myeloid leukemia after in-vitro purging with an anti-lacto-N-fucopentaose III antibody and rabbit complement. Leukemia Research, 1987, 11, 265-272.	0.8	14
207	Cryopreserved autologous bone marrow infusion following high dose chemotherapy in patients with acute myeloblastic leukemia in first relapse. Leukemia Research, 1985, 9, 407-412.	0.8	28
208	Treatment of multiple myeloma: A randomized study of three different regimens. Leukemia Research, 1985, 9, 1043-1049.	0.8	20
209	Sequential combination of high dose ARA-C (HiDAC) and asparaginase (ASP) for the treatment of advanced acute leukemia and lymphoma. Leukemia Research, 1984, 8, 729-735.	0.8	24
210	Vindesine in the treatment of refractory hematologic malignancies: A phase II study. Leukemia Research, 1982, 6, 649-652.	0.8	10
211	Therapy of Acute Nonlymphocytic Leukemia in Children: A Review of 73 Patients. Tumori, 1981, 67, 209-214.	1.1	2
212	Discontinuing therapy in childhood acute lymphocytic leukemia a multicentric survey in Italy. Cancer, 1980, 46, 1319-1323.	4.1	24
213	Combination chemotherapy for acute lymphocytic leukemia in adults: Results of a retrospective study in 82 patients. American Journal of Hematology, 1980, 8, 175-183.	4.1	30
214	Blast cell kinetics and prognosis in acute nonlymphocytic leukemia. Leukemia Research, 1980, 4, 239-244.	0.8	12
215	Daunorubicin, cytosine arabinoside and 6-thioguanine (DAT) combination chemotherapy for the treatment of acute non-lymphocytic leukemia. Leukemia Research, 1979, 3, 147-152.	0.8	10
216	Lack of prognostic significance of the pretreatment labeling and mitotic indices of marrow blasts in acute nonlymphocytic leukemia (ANLL). Cancer, 1978, 41, 1154-1160.	4.1	30